Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Syneos Health Inc (SYNH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,917,878
  • Shares Outstanding, K 103,230
  • Annual Sales, $ 2,672 M
  • Annual Income, $ -138,470 K
  • 36-Month Beta 0.97
  • Price/Sales 1.85
  • Price/Cash Flow 13.36
  • Price/Book 1.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.74
  • Number of Estimates 6
  • High Estimate 0.76
  • Low Estimate 0.72
  • Prior Year 0.67
  • Growth Rate Est. (year over year) +10.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.48 +4.75%
on 11/20/18
53.84 -11.52%
on 12/03/18
-3.36 (-6.59%)
since 11/09/18
3-Month
43.13 +10.46%
on 10/25/18
53.84 -11.52%
on 12/03/18
+0.49 (+1.04%)
since 09/10/18
52-Week
31.10 +53.18%
on 02/22/18
53.95 -11.70%
on 08/03/18
+8.09 (+20.46%)
since 12/08/17

Most Recent Stories

More News
John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman

Syneos Health(TM) (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that John M. Dineen has been appointed to the Company's Board of Directors and named...

SYNH : 47.64 (-0.71%)
CTSH : 67.09 (-1.34%)
MACK : 4.26 (+0.47%)
SYNH vs. CRL: Which Stock Is the Better Value Option?

SYNH vs. CRL: Which Stock Is the Better Value Option?

SYNH : 47.64 (-0.71%)
CRL : 127.71 (-0.89%)
Syneos Health Releases the 2019 Health Trend Ten, Outlining Critical Shifts Impacting Drug Development and Commercialization

Syneos Health(TM) (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released a trends forecast outlining critical shifts and the underlying dynamics that will shape...

SYNH : 47.64 (-0.71%)
Syneos Health Announces Corporate Leadership Positions

Jonathan Olefson Joins as General Counsel and Corporate Secretary

SYNH : 47.64 (-0.71%)
Zacks.com featured highlights include: Gray Television, Syneos, Dollar General, Sabre and Jones Lang

Zacks.com featured highlights include: Gray Television, Syneos, Dollar General, Sabre and Jones Lang

GTN : 17.21 (-0.41%)
DG : 105.64 (+2.86%)
SYNH : 47.64 (-0.71%)
SABR : 25.04 (+0.20%)
JLL : 130.10 (-2.47%)
5 Cheap GARP Picks With Discounted PEG

To make a long-term investment more effective, the principles of both value and growth strategies need to be combined.

GTN : 17.21 (-0.41%)
DG : 105.64 (+2.86%)
SYNH : 47.64 (-0.71%)
SABR : 25.04 (+0.20%)
JLL : 130.10 (-2.47%)
Syneos Health (SYNH) Tops Q3 Earnings and Revenue Estimates

Syneos Health (SYNH) delivered earnings and revenue surprises of 10.29% and 0.44%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

SYNH : 47.64 (-0.71%)
Syneos Health Reports Third Quarter 2018 Results

Highlights

SYNH : 47.64 (-0.71%)
Express Scripts (ESRX) Soars to 52-Week High, Time to Cash Out?

Express Scripts (ESRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

MEDP : 57.70 (-0.02%)
ESRX : 96.01 (+0.17%)
SYNH : 47.64 (-0.71%)
PRAH : 104.90 (+1.78%)
Syneos Health (SYNH) Earnings Expected to Grow: Should You Buy?

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SYNH : 47.64 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade SYNH with:

Business Summary

INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention,...

See More

Key Turning Points

2nd Resistance Point 49.85
1st Resistance Point 48.75
Last Price 47.64
1st Support Level 46.32
2nd Support Level 44.99

See More

52-Week High 53.95
Last Price 47.64
Fibonacci 61.8% 45.22
Fibonacci 50% 42.53
Fibonacci 38.2% 39.83
52-Week Low 31.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar